Literature DB >> 16691251

Prognostic factors for visual acuity improvement after intravitreal triamcinolone injection.

S Shulman1, J R Ferencz, G Gilady, Y Ton, E Assia.   

Abstract

PURPOSE: In some patients with macular oedema, intravitreal triamcinolone acetonide injection (IVTA) fails to improve visual acuity, although oedema shows clinical and angiographic improvement. Side effects can include increased intraocular pressure, cataract development, and (rarely) endophthalmitis. Our purpose was to identify prognostic factors for visual acuity improvement after IVTA.
METHODS: Data on patients treated by IVTA for macular oedema were retrospectively reviewed. Three months postinjection, visual acuity was rated as 'improved' (two or more Snellen lines gained) or 'nonimproved' (unchanged or worsened). Comparative demographic data and pre- and post-IVTA clinical and fluorescein angiographic findings were analysed with SPSS software.
RESULTS: Of 57 eyes (57 patients), 27 (47%) improved after IVTA. Initial visual acuity ('good', 'moderate', or 'poor') and aetiology of macular oedema (diabetic, venous occlusion, or pseudophakic) did not differ between the two groups. Improvement occurred in significantly more eyes with clinical or angiographic evidence of cystoid macular oedema (CME) than in those with diffuse retinal thickening (P=0.04) or diffuse leakage on fluorescein angiography (P=0.02), respectively, and in significantly more pseudophakic than phakic eyes (P=0.046).
CONCLUSIONS: Pseudophakia and clinical or angiographic CME, but not aetiology or initial visual acuity, were prognostic of visual acuity improvement after IVTA for macular oedema.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16691251     DOI: 10.1038/sj.eye.6702408

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  3 in total

1.  Effect of a single intravitreal bevacizumab injection on different optical coherence tomographic patterns of diabetic macular oedema.

Authors:  A Koytak; M Altinisik; E Sogutlu Sari; O Artunay; J C Umurhan Akkan; K Tuncer
Journal:  Eye (Lond)       Date:  2013-03-08       Impact factor: 3.775

Review 2.  Diabetic macular edema: what is focal and what is diffuse?

Authors:  David J Browning; Michael M Altaweel; Neil M Bressler; Susan B Bressler; Ingrid U Scott
Journal:  Am J Ophthalmol       Date:  2008-09-05       Impact factor: 5.258

3.  Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema.

Authors:  Hatem M Marey; Amin F Ellakwa
Journal:  Clin Ophthalmol       Date:  2011-07-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.